Navigation Links
Advanced Life Sciences Announces First Quarter 2008 Financial Results
Date:5/7/2008

nue studies with the National Institute of Allergy and Infectious

Diseases (NIAID) and the U.S. Army Medical Research Institute for

Infectious Diseases (USAMRIID) to explore cethromycin's activity against

high-priority bioterror agents for its use as a broad spectrum

countermeasure. Submit proposals to the Department of Defense and the

Department of Health and Human Services to fund the advanced development

of cethromycin in combating bioterror agents such as anthrax, tularemia,

plague and Burkholderia pseudomallei;

* Initiate enrollment by the end of the summer in Phase I/II

dose-escalating study to assess the safety, tolerability, and

preliminary efficacy of ALS-357 topically administered to patients with

cutaneous metastatic melanoma;

* Present cethromycin clinical data at ICAAC in the Fall.

Financial Guidance for 2008

Advanced Life Sciences expects its 2008 cash requirements excluding milestone payments that become due upon NDA filing to fall in the range of $16 million and $17 million. The first quarter cash use of $5.7 million reflects continued NDA submission costs that will curtail substantially in the coming quarters. Accordingly, we expect our quarterly cash use to decrease as we move forward with our operations. The cash used will be applied toward remaining cethromycin NDA submission activities, manufacturing costs, medical communication investments, ALS-357 clinical costs, and general operating expenses. We believe that this cash balance will be sufficient to allow us to progress into a commercial partnership which will support the ongoing funding needs of the Company.

Conference Call Details

Advanced Life Sciences will host a conference call and live webcast at 10:00 a.m. Eastern Time on Wednesday, May 7, 2008 to discuss the Company's financial results for the first quarter.

The conference call will be webcast simultaneously o
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast
2. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
3. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
4. Advanced Life Sciences Regains Compliance With Nasdaq Listing Requirements
5. Advanced Life Sciences Announces Plan to Submit NDA for Cethromycin
6. Encision Launches Next Generation of EnTouch(R) Handles for Advanced Laparoscopic Procedures
7. Advanced Life Sciences Receives Nasdaq Notification
8. Advanced Life Sciences Announces Fourth Quarter and Full Year 2007 Financial Results
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Advanced Life Sciences To Host 2008 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
11. Advanced Medical Specialties Joins US Oncology Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced several new ... in North America , the Middle ... "Bidding activity in 2015 continues to be robust" said Derek ... for bidding in 2014, we are pleased to see the bidding ... organization,s renewed focus on select market segments where we can add ...
(Date:3/3/2015)... March 3, 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), ... technologies and products for advanced microarray diagnostics, today ... CFE  to its Management team. In his capacity ... its transition from a development stage to a ... advance the Company,s capital market strategy and to ...
(Date:3/3/2015)... 03, 2015 Crown Bioscience, Inc., a ... launched a new Life Science division specializing in in ... , The first products released include in vivo ... soon to be released in vivo grade monoclonal antibodies ... expand their life science portfolio with additional antibody products ...
(Date:3/3/2015)... The winners of awards for supply chain ... Global Supply Chain Resiliency Council (GSCRC) at ... February 25th, 2015, at the Hyatt Regency in Santa ... together supply chain risk management and resiliency practitioners with ... through opportunities to collaborate, develop and share best practices, ...
Breaking Biology Technology:SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Crown Bioscience Launches Life Science Product Catalog 2Global Supply Chain Resiliency Council Names Award Winners 2Global Supply Chain Resiliency Council Names Award Winners 3Global Supply Chain Resiliency Council Names Award Winners 4
... Jan. 27 Alfacell Corporation (OTC Bulletin Board: ACEL) ... with the U.S. Food and Drug Administration (FDA) to ... of the ONCONASE rolling New Drug Application (NDA) for ... At the pre-NDA meeting, the FDA provided guidance to ...
... RELY ON INFORMATION PUBLISHED BY UNIVERSAL , NETTLETON, ... Sheets: UBRG) announces that certain unauthorized inaccurate information ... report on BeaconEquity.com website, potentially other websites and ... these materials, the company has found errors in ...
... Webcast Scheduled for Tuesday, February 3, 2009 SAN DIEGO, ... NBIX ) announced today that the Company will report ... the Nasdaq market closes on Tuesday, February 3, 2009. ... webcast to discuss its financial results and provide a ...
Cached Biology Technology:Alfacell Provides ONCONASE(R) NDA Submission Update 2Alfacell Provides ONCONASE(R) NDA Submission Update 3Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results 2
(Date:2/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/sxwl43/global_2d_gesture ) ... 2D Gesture Recognition Market 2015-2019" report to ... the Global 2D Gesture Recognition market to grow ... 2014-2019 The increased demand for gesture-enabled ... the major trends in the market. The growing ...
(Date:2/12/2015)... 2015   MedNet Solutions , a global ... management systems, has recently bolstered its ... iMedNet as the eClinical solution ... healthcare consultants.  Building on the Program,s existing benefits ... numerous co-marketing opportunities), MedNet,s new and improved program ...
(Date:2/5/2015)... , 5. Februar 2015 ... spezialisiertes Logistikunternehmen und hat eine neue Marketingkampagne ... Logistikfirma (Clinical Logistics Organization – CLO) der ... Kampagne lautet First , mit Schwerpunkt ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 Logo ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... with intelligence as a beneficial trait, according to ... Medical Center and other institutions. Jeremy Coplan, MD, ... found that high intelligence and worry both correlate ... the nutrient choline in theGlaxoSmithKline Pharmaceuticals, Sackler Institute ...
... Scientists at the Allen Institute for Brain Science have identified ... the brains of human individuals, and between humans and mice ... brain. The study, published online today in the journal ... and also serves as an introduction to what the associated ...
... - - Finger Vein Identity Management ... - - Hitachi Europe Ltd. and M2SYS ... partnership making M2SYS Hitachi,s primary Value Added Reseller in North ... Biometric Finger Vein identity management scanning technology was developed by ...
Cached Biology News:Excessive worrying may have co-evolved with intelligence 2Fine-scale analysis of the human brain yields insight into its distinctive composition 2Fine-scale analysis of the human brain yields insight into its distinctive composition 3M2SYS Technology Partners with Hitachi to Offer Innovative Biometric Finger Vein Scanner to US Market 2
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... DNase is a preparation of deoxyribonuclease ... DNA to produce 3-hydroxyl oligonucleotides. This ... applications where maintaining the integrity of ... qualified for use with the Core ...
... I, Wild Type Liquid. In 100 ... 200 µM EDTA, 20% glycerol, pH 7.9. AVOID ... is a monomeric protein of 765 amino acids ... relaxation of both positive and negative supercoiled DNAs ...
Request Info...
Biology Products: